NCT02194179View on ClinicalTrials.gov

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2007

Conditions
HIV Infections
Interventions
DRUG

NVP XR 400 mg (KCR 25%)

DRUG

NVP XR 400 mg (KCR 20%)

DRUG

NVP XR 300 mg (KCR 25%)

DRUG

NVP XR 300 mg (KCR 20%)

OTHER

high-fat breakfast

DRUG

NVP IR 200 mg (Viramune®)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY